Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
Ying Huang has spent the past seven years building up one of the leading cancer cell therapy players. Now, just weeks after announcing his departure as Legend Biotech's CEO, Huang is stepping ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.